Review Articles How to treat borderline resectable pancreatic cancer: current challenges and future directions Borderline resectable pancreatic cancer is a target for multidisciplinary therapeutic approaches. Reviews of recent articles and on-going studies identified the status and future directions of therapy. Takahashi, S.Jpn J Clin Oncol 2018 48:3 205–213, 10.1093/jjco/hyx191 Neuroblastoma Neuroblastoma is reviewed from the aspects of epidemiology, pathogenesis, spontaneous regression, genetic alterations, diagnosis, risk classification and therapy. The clinical studies are mainly focused on the Japanese protocols (JCCG). Nakagawara, A., Li, Y., Izumi, H., et al.Jpn J Clin Oncol 2018 48:3 214–241, 10.1093/jjco/hyx176 Original Articles Breast Medicine A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer In this Phase I/II study, a combination of oral vinorelbine and lapatinib is tolerable and fairly effective with some long-term responders in HER2-positive metastatic breast cancer. Chen, T W-W., Yeh, D-C., Chao, T-Y., et al.Jpn J Clin Oncol 2018 48:3 242–247, 10.1093/jjco/hyx188 Improved overall survival over recent decades in patients with hormone-receptor-positive, HER2-negative breast cancer: a single-center retrospective analysis of prognostic factors OS and RFS of HR-positive HER2-negative breast cancer patients significantly improved for two decades. It could be associated with early detection of tumor and history of hormone therapy. Yamada, Y., Mukai, H., Tokudome, Y., et al.Jpn J Clin Oncol 2018 48:3 248–254, 10.1093/jjco/hyy001 Gynecology Maintenance hormonal therapy after treatment with medroxyprogesterone acetate for patients with atypical polypoid adenomyoma Maintenance hormonal therapy after treatment with MPA was highly effective and safe, particularly in patients with BMI ≧24 kg/m2 and an irregular menstruation cycle. Nomura, H., Sugiyama, Y., Tanigawa, T., et al.Jpn J Clin Oncol 2018 48:3 255–258, 10.1093/jjco/hyx193 Radiation Oncology Clinical outcomes and prognostic factors of chemoradiotherapy for postoperative lymph node recurrence of esophageal cancer Approximately 28% of esophageal squamous cell carcinoma patients with lymph node recurrence after curative resection could achieve long-term survival with chemoradiotherapy. Treatment with 5-fluorouracil plus cisplatin or patients with a single regional recurrence might improve survival. Kawamoto, T., Nihei, K., Sasai, K., et al.Jpn J Clin Oncol 2018 48:3 259–264, 10.1093/jjco/hyx171 Impact of minimum point dose on local control and toxicity in T3–4 nasopharyngeal carcinoma treated with intensity-modulated radiation therapy plus chemotherapy Treatment for T3–4 NPC was trapped in a dilemma for increasing local control and protecting abutting neurologic structures. Dmin ≥ 54 Gy was found to confer acceptable local control with less toxicities. Xue, F., Hu, C., He, X.Jpn J Clin Oncol 2018 48:3 265–271, 10.1093/jjco/hyx183 The effect of escalating the boost dose for patients with involved resection margin after breast-conserving surgery A median boost dose of 15 Gy might be insufficient in patients younger than 40 years or with tumor size greater than 2 cm or involved radial resection margins. Park, S., Ahn, S D., Choi, E K., et al.Jpn J Clin Oncol 2018 48:3 272–277, 10.1093/jjco/hyy002 Public Health Report Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in Japan Cancer screening guidelines have been developed and revised based on the standardized method. These guidelines have contributed in promoting evidence-based cancer screening for national programs. Hamashima, C.Jpn J Clin Oncol 2018 48:3 278–286, 10.1093/jjco/hyx190 Short Communications Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery Chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer can prolong patient survival, but the estimated incidence of second primary cancer does not increase. Makimoto, G., Kubo, T., Oze, I., et al.Jpn J Clin Oncol 2018 48:3 287–290, 10.1093/jjco/hyy003 Characteristics of cellular composition in malignant pericardial effusion and its association with the clinical course of carcinomatous pericarditis Low neutrophil and high lymphocyte counts in malignant pericardial effusion were significantly associated with good effusion failure-free survival at 1 month. Oyakawa, T., Muraoka, N., Iida, K., et al.Jpn J Clin Oncol 2018 48:3 291–294, 10.1093/jjco/hyx187 Letters Prevention of IVR: a need for investigation Ouzaid, I., Xylinas, E., for the Young Academic Urologists of the European Association of Urology Urothelial Carcinoma GroupJpn J Clin Oncol 2018 48:3 295–296, 10.1093/jjco/hyx169 Author’s reply to ‘Prevention of IVR: a need for investigation’ Yamashita, S., Ito, A., Arai, Y.Jpn J Clin Oncol 2018 48:3 297, 10.1093/jjco/hyx192 Image of the Month Atypical radiological presentation of pulmonary invasion of diffuse large B-cell lymphoma mimicking Pneumocystis jiroveci pneumonia Higashiyama, R I., Makita, S., Maeshima, A M., et al.Jpn J Clin Oncol 2018 48:3 298–299, 10.1093/jjco/hyx194 Cancer Statistics Digest © The Author 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: email@example.com.
Japanese Journal of Clinical Oncology – Oxford University Press
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera